{"id":49726,"date":"2022-10-18T07:02:37","date_gmt":"2022-10-18T05:02:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/"},"modified":"2022-10-18T07:02:37","modified_gmt":"2022-10-18T05:02:37","slug":"bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/","title":{"rendered":"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs"},"content":{"rendered":"
\n

\nCompanies to Explore Opportunities to Integrate Biocorp\u2019s Injay\u00ae Technology with BD UltraSafePlus\u2122 Passive Needle Guard to Help Biopharmaceutical Manufacturers Capture and Transmit Self-Administered Injection Data.<\/i><\/b>\n<\/p>\n

FRANKLIN LAKES, N.J.–(BUSINESS WIRE)–#digitalhealth<\/a>–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in France, today announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics.\n<\/p>\n

\nTo support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp\u2019s Injay\u00ae technology \u2013 a solution designed to capture and transmit injection events using Near Field Communication (NFC) technology \u2013 to the BD UltraSafe Plus\u2122 Passive Needle Guard used with prefillable syringes.\n<\/p>\n

\n\u201cConnected drug delivery devices play an important role in helping biopharmaceutical manufacturers understand and track key trends in patient adherence,\u201d said Matthew Schabacker, vice president and general manager of Advanced Drug Delivery Solutions at BD. \u201cOur agreement with Biocorp enables us to explore innovative solutions in this market and further supports BD\u2019s commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes \u2014 as we combine Biocorp\u2019s expertise in developing and commercializing connected drug delivery devices to our existing portfolio of advanced injection drug delivery systems.\u201d\n<\/p>\n

\nBiocorp\u2019s Injay\u00ae is a simple and cost-effective connected solution designed to monitor the use of pre-fillable syringes in clinical studies or routine care. Through NFC technology and specific sensors to identify the product, it can confirm a complete injection and easily transfer that information to a smartphone.\n<\/p>\n

\n\u201cWe are very proud to announce this collaboration with BD, a worldwide leader in pre-filled syringes and safety device market,\u201d said Eric Dessertenne, CEO of Biocorp. \u201cIt shows the leading position of Biocorp in the field of smart drug delivery devices and addresses an unmet need in the market today.\u201d\n<\/p>\n

\nThe increased prevalence of self-administered therapies for chronic diseases coupled with the pervasiveness of digital technologies in everyone\u2019s life open new opportunities to improve outcomes and experience for patients and to increase the ability to monitor medication adherence.\n<\/p>\n

\nThe global connected drug delivery market is expected to grow at double digit growth rates1<\/sup> over the next decade \u2013 fueled by the transition from acute care settings to home care and the increased prevalence of self-administered therapies. Today, BD is a world leader in supplying prefillable syringes and safety systems to the biopharmaceutical industry \u2013 with approximately 70 percent of the top 100 biopharmaceutical companies using BD devices, and more than one billion BD UltraSafe\u2122 units2<\/sup> sold since 2010 being used to administer over 40 different drugs.3<\/sup>\n<\/p>\n

\nAbout BD<\/b>\n<\/p>\n

\nBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com<\/a> or connect with us on LinkedIn at www.linkedin.com\/company\/bd1\/<\/a> and Twitter @BDandCo<\/a>.\n<\/p>\n

\nAbout Biocorp<\/b>\n<\/p>\n

\nRecognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP’s product portfolio of innovative connected solutions. The company has 75 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 \u2013 ALCOR). For more information, please visit www.biocorpsys.com<\/a>.\n<\/p>\n

\n1<\/sup> Grandview Research CDDD Market<\/a>, Data Bridge Market Research Global CDDD Market<\/a>
2<\/sup> As of 2020
\n
3<\/sup> Drug products approved with BD UltraSafe\u2122 solutions. Includes both BD UltraSafe Passive\u2122 and BD UltraSafe Plus\u2122 passive needle guards\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBD<\/b>
Media<\/span>:
\n
Trey Hollern
\n
Director, Public Relations
\n
862.284.8629
\n
trey.hollern@bd.com<\/a>\n<\/p>\n

\nInvestors<\/span>:
\n
Francesca DeMartino
\n
SVP, Head of Investor Relations
\n
201.847.5743
\n
Francesca.demartino@bd.com<\/a>\n<\/p>\n

\nBIOCORP<\/b>
Sylvaine Dessard
\n
Marketing & Communication Director
\n
rp@biocorp.fr<\/a>\n<\/p>\n

\nBruno ARABIAN
\n
barabian@ulysse-communication.com<\/a>
+33 (0)6 87 88 47 26\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Companies to Explore Opportunities to Integrate Biocorp\u2019s Injay\u00ae Technology with BD UltraSafePlus\u2122 Passive Needle Guard to Help Biopharmaceutical Manufacturers Capture and Transmit Self-Administered Injection Data. FRANKLIN LAKES, N.J.–(BUSINESS WIRE)–#digitalhealth–Regulatory News: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49726","6":"format-standard","7":"category-industry"},"yoast_head":"\nBD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Companies to Explore Opportunities to Integrate Biocorp\u2019s Injay\u00ae Technology with BD UltraSafePlus\u2122 Passive Needle Guard to Help Biopharmaceutical Manufacturers Capture and Transmit Self-Administered Injection Data. FRANKLIN LAKES, N.J.–(BUSINESS WIRE)–#digitalhealth–Regulatory News: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-18T05:02:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221017006035\/en\/1319210\/21\/LOGO-BLEU.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs\",\"datePublished\":\"2022-10-18T05:02:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/\"},\"wordCount\":807,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221017006035\\\/en\\\/1319210\\\/21\\\/LOGO-BLEU.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/\",\"name\":\"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221017006035\\\/en\\\/1319210\\\/21\\\/LOGO-BLEU.jpg\",\"datePublished\":\"2022-10-18T05:02:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221017006035\\\/en\\\/1319210\\\/21\\\/LOGO-BLEU.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221017006035\\\/en\\\/1319210\\\/21\\\/LOGO-BLEU.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/","og_locale":"en_US","og_type":"article","og_title":"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs - Pharma Trend","og_description":"Companies to Explore Opportunities to Integrate Biocorp\u2019s Injay\u00ae Technology with BD UltraSafePlus\u2122 Passive Needle Guard to Help Biopharmaceutical Manufacturers Capture and Transmit Self-Administered Injection Data. FRANKLIN LAKES, N.J.–(BUSINESS WIRE)–#digitalhealth–Regulatory News: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-18T05:02:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221017006035\/en\/1319210\/21\/LOGO-BLEU.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs","datePublished":"2022-10-18T05:02:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/"},"wordCount":807,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221017006035\/en\/1319210\/21\/LOGO-BLEU.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/","url":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/","name":"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221017006035\/en\/1319210\/21\/LOGO-BLEU.jpg","datePublished":"2022-10-18T05:02:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221017006035\/en\/1319210\/21\/LOGO-BLEU.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221017006035\/en\/1319210\/21\/LOGO-BLEU.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bd-biocorp-sign-agreement-to-bring-connectivity-traceability-to-self-administered-injectable-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49726"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49726\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}